• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Prothena Corporation plc

    11/13/24 6:06:27 AM ET
    $PRTA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PRTA alert in real time by email
    SC 13G/A 1 d853309dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G/A

    Under the Securities Exchange Act of 1934

    (Amendment No. 1) *

     

     

    Prothena Corporation PLC

    (Name of Issuer)

    Ordinary Shares, $0.01 par value

    (Title of Class of Securities)

    G72800108

    (CUSIP Number)

    Diana L. Hayes, Esq.

    Trenam Law

    2700 Bank of America Plaza

    Tampa, Florida 33602

    813-227-7433

    (Name, Address and Telephone Number of Person Authorized to

    Receive Notices and Communications)

    September 30, 2024

    (Date of Event which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (the “Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes ).

     

     

     


    CUSIP No. G72800108    Schedule 13G/A    Page 2 of 5 Pages

     

     1   

     NAME OF REPORTING PERSON

     

     William P. Scully

     2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Florida

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

      SOLE VOTING POWER

     

     694,313*

       6  

      SHARED VOTING POWER

     

     3,341,827*

       7  

      SOLE DISPOSITIVE POWER

     

     694,313*

       8  

      SHARED DISPOSITIVE POWER

     

     3,341,827*

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     4,036,140*

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     7.50%*

    12  

     TYPE OF REPORTING PERSON

     

     IN

    * See Item 4.


    CUSIP No. G72800108    Schedule 13G/A    Page 3 of 5 Pages

     

    Item 1.

     

      (a)

    Name of Issuer:

    Prothena Corporation PLC

     

      (b)

    Address of Issuer’s Principal Executive Office:

    77 Sir John Rogerson’s Quay, Block C

    Grand Canal Docklands

    Dublin 2, D02 VK60, Ireland

    Item 2.

     

      (a)

    The name of the Reporting Person is William P. Scully.

     

      (b)

    The address of the Reporting Person is 771 Manatee Cove, Vero Beach, Florida 32963.

     

      (c)

    The citizenship of the Reporting Person is Florida.

     

      (d)

    Title and class of securities: Ordinary Shares, $0.01 par value

     

      (e)

    CUSIP No: G72800108

    Item 3.

    If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)    ☐    Broker or dealer registered under section 14 of the Act (15 U.S.C. 78o)
    (b)    ☐    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c)
    (c)    ☐    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c)
    (d)    ☐    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8)
    (e)    ☐    An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E)
    (f)    ☐    An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F)
    (g)    ☐    A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G)
    (h)    ☐    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813)
    (i)    ☐    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3)
    (j)    ☐    A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J)
    (k)    ☐    Group, in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____

    Not applicable

     

    Item 4.

    Ownership.

     

      (a)

    Amount beneficially owned:

    The Reporting Person may be deemed to be the beneficial owner of 4,036,140 Ordinary Shares. This amount consists of (i) 69,213 Ordinary Shares owned directly by the Reporting Person over which he has sole voting and dispositive power, (ii) 72,100 Ordinary Shares owned by Manatee Equity Fund LLC, of which the Reporting Person is the sole manager with sole voting and dispositive power, (iii) 553,000 Ordinary Shares owned by the Reporting Person’s IRA, over which he has sole voting and dispositive power, (iv) 42,000 Ordinary Shares owned by the Reporting Person’s spouse’s IRA, over which he may be deemed to have shared voting and dispositive power, (v) 57,000 Ordinary Shares owned by the Reporting Person’s spouse, over which he may be deemed to have shared voting and dispositive power


    CUSIP No. G72800108    Schedule 13G/A    Page 4 of 5 Pages

     

    (vi) 14,000 Ordinary Shares owned by an IRA subject to an investment management agreement over which the Reporting Person may be deemed to have shared voting and dispositive power by reason of his right to terminate such agreement, (vii) 60,000 Ordinary Shares owned in the aggregate by a trust, of which the Reporting Person may be deemed to have shared voting and dispositive power by virtue of being a co-trustee, (viii) 2,709,846 Ordinary Shares owned in the aggregate by various grantor retained annuity trusts, which have an independent trustee, but over which the Reporting Person may be deemed to have shared voting and dispositive power by reason of his retained right to substitute assets in such trusts, and (ix) 458,981 Ordinary Shares owned in the aggregate by various irrevocable gift trusts, which have an independent trustee, but over which the Reporting Person may be deemed to have shared voting and dispositive power by reason of his retained right to substitute assets in such trusts.

     

      (b)

    Percent of Class:

    According to the Issuer’s most recent Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, the number of shares outstanding as of August 1, 2024 was 53,780,345. The Ordinary Shares which the Reporting Person may be deemed to beneficially own constitute approximately 7.50% of such total number of shares. 

     

      (c)

    Number of shares as to which the Reporting Person has:

     

      i.

    Sole power to vote or direct the vote: 694,313

     

      ii.

    Shared power to vote or direct the vote: 3,341,827

     

      iii.

    Sole power to dispose or direct the disposition of: 694,313

     

      iv.

    Shared power to dispose or direct the disposition of: 3,341,827

    The Reporting Person disclaims beneficial ownership of all Ordinary Shares to which the Reporting Person does not have a pecuniary interest, and the Reporting Person expressly disclaims any status as a “group” with any other party.

     

    Item 5.

    Ownership of Five Percent or Less of a Class.

    Not applicable.

     

    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person.

    Not applicable.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

    Not applicable.

     

    Item 8.

    Identification and Classification of Members of the Group.

    Not applicable.

     

    Item 9.

    Notice of Dissolution of Group.

    Not applicable.

     

    Item 10.

    Certification.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.


    CUSIP No. G72800108    Schedule 13G/A    Page 5 of 5 Pages

     

    SIGNATURE

    After reasonable inquiry and to the best of his knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

    Dated: November 13, 2024

     

    WILLIAM P. SCULLY, individually

    /s/ Diana L. Hayes

    Diana L. Hayes, Attorney-in-fact*

     

    *

    Pursuant to a Limited Power of Attorney dated as of February 13, 2024, a copy of which is on file with the Commission.

    Get the next $PRTA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PRTA

    DatePrice TargetRatingAnalyst
    5/28/2025$4.00Neutral → Underperform
    BofA Securities
    5/27/2025Outperform → Perform
    Oppenheimer
    5/27/2025$6.00Buy → Hold
    Jefferies
    5/27/2025Overweight → Neutral
    Cantor Fitzgerald
    12/20/2024$40.00Buy
    Chardan Capital Markets
    1/30/2024$68.00 → $38.00Buy → Neutral
    BofA Securities
    12/12/2023$62.00Buy
    Deutsche Bank
    4/24/2023$80.00Outperform
    SVB Securities
    More analyst ratings

    $PRTA
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Prothena Corporation plc

    SCHEDULE 13G/A - PROTHENA CORP PUBLIC LTD CO (0001559053) (Subject)

    8/14/25 1:07:20 PM ET
    $PRTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Prothena Corporation plc

    SCHEDULE 13G/A - PROTHENA CORP PUBLIC LTD CO (0001559053) (Subject)

    8/13/25 4:14:07 PM ET
    $PRTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Prothena Corporation plc

    S-8 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Filer)

    8/8/25 4:30:29 PM ET
    $PRTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRTA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Scully William P received a gift of 430,000 units of Ordinary Shares, bought $2,749,916 worth of Ordinary Shares (207,436 units at $13.26) and gifted 747,700 units of Ordinary Shares, decreasing direct ownership by 7% to 735,993 units (SEC Form 4)

    4 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)

    5/2/25 10:29:05 AM ET
    $PRTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRTA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Prothena Announces that Novo Nordisk Will Advance Coramitug (Formerly PRX004) into Phase 3 Development for ATTR Amyloidosis with Cardiomyopathy

    Coramitug is a potential first-in-class amyloid depleter antibody for the treatment of ATTR amyloidosis with cardiomyopathy1-3 Novo Nordisk successfully completed a Phase 2 trial with coramitug and is expected to initiate a Phase 3 program in 2025 Prothena to earn a clinical milestone payment when prespecified enrollment criteria are met in a Phase 3 clinical trial by Novo Nordisk Prothena Corporation plc (NASDAQ:PRTA), announced that Novo Nordisk communicated during their second quarter 2025 earnings call on August 6, 2025 that they expect to advance coramitug, a potential first-in-class amyloid depleter antibody, into a Phase 3 program for ATTR amyloidosis with cardiomyopathy (A

    8/6/25 9:00:00 AM ET
    $PRTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Prothena Reports Second Quarter 2025 Financial Results and Business Highlights

    Net cash used in operating and investing activities was $46.4 million in the second quarter and net cash used in operating and investing activities was $99.8 million for the first six months of 2025; quarter-end cash and restricted cash position was $372.3 million Prothena expects to convene an Extraordinary General Meeting by year-end 2025 to propose that shareholders approve a reduction of share capital to create distributable reserves in order to support a potential share redemption program if deemed appropriate Roche to advance prasinezumab, a potential first-in-class anti-alpha-synuclein antibody targeting a known biological driver of Parkinson's disease progression, into Phase

    8/4/25 4:05:00 PM ET
    $PRTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Prothena to Report Second Quarter 2025 Financial Results on August 4

    Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its second quarter and first six months of 2025 financial results on Monday, August 4, 2025, after the close of the U.S. financial markets. Consistent with past practice, the Company will not be conducting a conference call in conjunction with the financial results release on August 4. About Prothena Prothena Corporation plc is a late-stage clinical biotechnology company with expertise in protein dysregulation and a pipeline of investigational therapeutics with the potent

    7/28/25 4:05:00 PM ET
    $PRTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRTA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Prothena downgraded by BofA Securities with a new price target

    BofA Securities downgraded Prothena from Neutral to Underperform and set a new price target of $4.00

    5/28/25 8:10:50 AM ET
    $PRTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Prothena downgraded by Oppenheimer

    Oppenheimer downgraded Prothena from Outperform to Perform

    5/27/25 9:09:16 AM ET
    $PRTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Prothena downgraded by Jefferies with a new price target

    Jefferies downgraded Prothena from Buy to Hold and set a new price target of $6.00

    5/27/25 9:09:16 AM ET
    $PRTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRTA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Scientific Officer Zago Wagner M. was granted 85,000 units of Ordinary Shares (SEC Form 4)

    4 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)

    7/30/25 5:52:29 PM ET
    $PRTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Accounting Officer Walker Karin L was granted 25,000 units of Ordinary Shares (SEC Form 4)

    4 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)

    7/30/25 5:52:14 PM ET
    $PRTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Development Officer Swanson Chad J. was granted 85,000 units of Ordinary Shares (SEC Form 4)

    4 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)

    7/30/25 5:52:01 PM ET
    $PRTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRTA
    Leadership Updates

    Live Leadership Updates

    View All

    Prothena Reports Third Quarter 2024 Financial Results and Business Highlights

    Net cash used in operating and investing activities was $45.2 million and $102.5 million for the third quarter and first nine months of 2024, respectively; quarter-end cash and restricted cash position was $520.1 million PRX012, a potential single-injection once-monthly subcutaneous treatment, is designed to address the unmet need of millions of patients with presymptomatic or early symptomatic Alzheimer's disease; Prothena expects to report multiple clinical readouts starting in mid-2025 and continuing throughout the year from the ongoing Phase 1 ASCENT clinical trials Results from partner Roche evaluating prasinezumab in patients with early Parkinson's disease from the Phase 2 PASA

    11/12/24 4:05:00 PM ET
    $PRTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Prothena Reports First Quarter 2024 Financial Results and Business Highlights

    Net cash used in operating and investing activities was $73.2 million in the first quarter of 2024; quarter-end cash and restricted cash position was $548.7 million Advanced potential best-in-class Alzheimer's disease portfolio: initial data supportive of ongoing Phase 1 clinical trial for PRX012, an anti-amyloid beta antibody; received FDA clearance for IND application and Fast Track designation for PRX123, a dual amyloid beta/tau vaccine; Phase 2 clinical trial initiated in patients with early Alzheimer's disease for BMS-986446 (formerly PRX005) by partner Bristol Myers Squibb Strengthened leadership position in the amyloidosis community with ongoing enrollment of the confirmatory

    5/8/24 4:05:00 PM ET
    $PRTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Prothena Appoints David Ford to Newly Created Chief People Officer Position

    Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it has named David Ford to a newly created position of Chief People Officer, reporting to Prothena President and Chief Executive Officer Gene Kinney, PhD. In this role, Mr. Ford will be responsible for people, culture, and human resources strategy to drive the company's vision and overall growth strategy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240304692974/en/David Ford, Chief People Officer, Prothena (Photo: Business Wire

    3/4/24 4:05:00 PM ET
    $PRTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRTA
    Financials

    Live finance-specific insights

    View All

    Prothena to Report Second Quarter 2025 Financial Results on August 4

    Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its second quarter and first six months of 2025 financial results on Monday, August 4, 2025, after the close of the U.S. financial markets. Consistent with past practice, the Company will not be conducting a conference call in conjunction with the financial results release on August 4. About Prothena Prothena Corporation plc is a late-stage clinical biotechnology company with expertise in protein dysregulation and a pipeline of investigational therapeutics with the potent

    7/28/25 4:05:00 PM ET
    $PRTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Prothena to Report First Quarter 2025 Financial Results on May 8

    Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its first quarter 2025 financial results on Thursday, May 8, 2025, after the close of the U.S. financial markets. Consistent with past practice, the Company will not be conducting a conference call in conjunction with the financial results release on May 8. About Prothena Prothena Corporation plc is a late-stage clinical biotechnology company with expertise in protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of deva

    5/1/25 4:05:00 PM ET
    $PRTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Prothena Reports Fourth Quarter and Full Year 2024 Financial Results, and Provides Financial Guidance and Business Highlights

    Net cash used in operating and investing activities was $47.8 million in the fourth quarter and $150.3 million for the full year of 2024; quarter-end cash and restricted cash position was $472.2 million The company expects cash guidance for the full year 2025 net cash used in operating and investing activities to be $168 to $175 million and expects to end the year with approximately $301 million in cash (midpoint) Topline results expected in 2Q 2025 from the confirmatory Phase 3 AFFIRM-AL clinical trial of birtamimab in patients with Mayo Stage IV AL amyloidosis being conducted under a SPA agreement with the FDA with a primary endpoint of all-cause mortality (time-to-event) at a statis

    2/20/25 4:05:00 PM ET
    $PRTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRTA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Prothena Corporation plc

    SC 13G/A - PROTHENA CORP PUBLIC LTD CO (0001559053) (Subject)

    11/14/24 1:22:34 PM ET
    $PRTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Prothena Corporation plc

    SC 13G/A - PROTHENA CORP PUBLIC LTD CO (0001559053) (Subject)

    11/13/24 7:00:50 AM ET
    $PRTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Prothena Corporation plc

    SC 13G/A - PROTHENA CORP PUBLIC LTD CO (0001559053) (Subject)

    11/13/24 6:06:27 AM ET
    $PRTA
    Biotechnology: Pharmaceutical Preparations
    Health Care